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Abstract: Many neurodegenerative diseases (NDDs) have been thought to be caused mainly by conditions that were 
not controlled by genetic inheritance. Extensive research into these diseases has recently discovered that perhaps a 
majority of them have genetic inheritance components. Once thought to be a rare form of NDD, frontotemporal 
degeneration (FTD) is now considered to be the main cause of early onset NDD, and the information on genetic causes 
and inheritance has increased dramatically over the last 10 years. The main genes that have been found to be involved 
in frontotemporal degeneration, MAPT, TARDBP, GRN C9orf72, VCP, FUS, and CHMP2B, have also been found in 
related diseases such as Alzheimer’s disease, Amyotrophic Lateral Sclerosis, and Parkinson’s disease. This paper is 
intended as an updated review of the genetic causes of FTD. This information should aid physicians and scientists in 
understanding the current concepts, and encourage even more genetic testing so that a full knowledge of genetic 
inheritance in FTD will be soon be forthcoming. 
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INTRODUCTION 
Frontotemporal Degeneration (FTD – also known as 
frontotemporal dementia; and frontotemporal lobar 
degeneration - FTLD) has, until recently, been 
considered to be a relatively uncommon disease, so 
little was known about the cause. In fact, there is no 
one single cause, either genetic or not, but many 
possibilities exist. Because there can be so many 
causes, the symptoms of the disease vary greatly 
among those affected. This leads to difficulties in 
diagnosis and potential treatment options. In order to 
effectively treat a disease, the medical community 
needs to know as much as possible about the causes.  
FTD is a disease that is commonly caused by a 
mutation (or mutations), in one or more genes. The 
best way to develop treatment options is to do as many 
genetic studies as possible on FTD patients and their 
families. About 40-50% of FTD patients have a family 
history of related disorders [1, 2]. Unfortunately, 
funding for these genetic studies has not been readily 
available; in part because much of the funding comes 
from drug companies that are most interested in 
producing treatment options, and in part because these 
types of studies are time consuming and difficult. 
Therefore, the current data that is available on these 
diseases may still not accurately reflect how many 
people are affected as a result of inheritance (gene 
passed down from parents) vs. sporadic disease 
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(mutation has no known family inheritance). It has been 
estimated that having a family history of at least one 
first-degree relative with dementia is the reality for 25% 
of people 55 years of age and older [3]. Unfortunately, 
the accuracy in determining a family history of disease 
is complicated by the variation in disease presentation 
found in these disorders. This article gives an overview 
of the potential genetic causes (from what is currently 
known), and will discuss in a little more detail some of 
the leading genetic causes.  
When we think about the dementia related diseases 
we tend to think in discrete diagnoses (Alzheimer’s, 
FTD, etc.). In reality, all of these dementias overlap in 
symptoms and causes, etc., depending on the protein 
(and other processes) involved. In general, FTD and 
the diseases most closely linked to FTD (ALS, PD), 
have an age of onset of disease before 65; while AD 
patients generally have a later onset [4, 5]. There are 
some common genes that are associated with many 
types of dementias and related disorders, such as 
Parkinson’s (PD) and ALS (amyotrophic lateral 
sclerosis – Lou Gehrig’s disease). For example, there 
is a region on chromosome 17 that is a hot spot for 
diseases such as Alzheimer’s disease (AD), FTD, and 
Parkinson’s disease [1]. There are also multiple genes 
that may possibly be involved in one or more of these 
diseases. This is what makes understanding the 
causes, and developing effective therapies so difficult. 
FRONTAL AND TEMPORAL LOBE FUNCTIONS  
The name FTD is descriptive of the parts of the 
brain that are affected, the frontal and temporal lobes. 
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The main functions of the frontal lobe include decision 
making, complex problem solving, social skills, impulse 
control, empathy, conscience, and working memory 
and recall. The primary motor cortex area of the frontal 
lobe, which is anterior to the central sulcus, is involved 
in management of speech production, and in voluntary 
movement. The temporal lobe functions include the 
regulation of memory, and recognition and 
understanding of spoken words [6]. Depending on 
which areas of these lobes are affected by the specific 
genetic mutations, there will be a variety of symptoms 
observed. 
BASICS OF NEURODEGENERATIVE DISEASE 
The basis of neurodegenerative diseases is that 
brain cells (neurons) are dying. This loss of neurons 
leads to loss of a potential multitude of abilities (from 
loss of executive decision making to loss of mobility, 
etc.), depending on where in the brain the cells are 
dying. The main reason that the cells die is that they 
commit suicide (apoptosis). Cells in our bodies are 
programmed to go through apoptosis when processes 
in the cell become faulty (this is a protective 
mechanism, usually for our benefit). In the case of 
FTDs, there is an accumulation (many times an 
aggregation) of proteins in the cell (quite often this is 
due to gene mutations that produce faulty proteins), 
and eventually the cell dies. In a normally functioning 
cell, any abnormal or misfunctional proteins are usually 
bound by ubiquitin. These abnormal proteins are then 
ushered to a proteasome where they are degraded. In 
FTDs, the abnormal proteins are not able to be 
degraded, and so accumulate in the cell. When this 
occurs the cell will signal itself to go through apoptosis 
[7]. Sometimes the aggregates contain what should be 
normally functioning proteins [8, 9]. Mutations in other 
proteins (or yet unknown processes) may be the cause 
of these aggregates, but the result is the same – cell 
death. There are also several other proteins (or 
potential proteins – functions yet unknown) that are 
involved in neurodegenerative dementias. The most 
common of these known proteins, their genes, and 
gene mutations will be discussed in this work. 
INHERITANCE IN NEURODEGENERATIVE DISEASE 
Within the last 10 years or so, the main ideas about 
inheritance in the FTD related diseases have changed 
dramatically, primarily due to the massive amount of 
new information that researchers have been able to 
discover during that time. While it was initially believed 
that these diseases were primarily caused by sporadic 
mutations [10, 11], it is now believed that the majority 
of cases may actually be transmitted via familial 
inheritance [12]. For the disorders and genes that will 
be covered here, the type of inheritance is autosomal 
dominant. While the issue of penetrance is being 
researched [3, 13], it is currently almost impossible to 
determine penetrance with any accuracy due to the 
basic genetics involved. Not only are these diseases 
caused via autosomal dominant transmission, there are 
also almost no known cases of patients who are 
homozygous for a mutation. The fact that patients are 
heterozygous for mutations, plus other factors (most 
yet unknown), makes disease presentation, age of 
onset, etc. extremely variable. Therefore, the concept 
of penetrance in these diseases seems to be moot. 
Hopefully, in a few years we will know enough about 
the genetics of these diseases to have pertinent 
information on penetrance. 
PATHOLOGY OF NEURODEGENERATIVE DISEASE  
The histopathology of the neurons in these diseases 
is mainly based on detection of the accumulated 
normal or abnormal proteins, known generally as 
cellular inclusions. There are a number of different 
categories that define these diseases, but no one 
category is specific to any individual disease. There are 
two major categories of pathology described; those 
cells with tau protein inclusions (around 40%), and 
those without tau (around 50%) [14, 15]. Those cells 
without tau protein inclusions most commonly contain 
TAR DNA-binding protein 43 (TDP-43) protein 
inclusions; less commonly, FUS proteins, and a small 
minority apparently contain ubiquitin inclusions with no 
other proteins included, or no inclusions [16]. Table 1 
summarizes the genetic pathology of genes associated 
with FTD. 
MAPT 
The tau protein is produced by the MAPT 
(microtubule-associated protein tau) gene, which is 
located on chromosome 17 (17q21.1) in that hot spot 
region that was mentioned earlier. It is expressed 
primarily in neurons, and the tau protein functions by 
binding to microtubules to facilitate their polymerization, 
thus helping in stabilization [17]. Mutations which allow 
the protein to be hyperphosphorylated are known to be 
a major cause of disease [18, 19]. Mutations that cause 
the loss of the ability of tau to bind to microtubules or 
promote the assembly of tau filaments are know to be 
responsible for about 5% of FTDs [16]. There are at 
least 50 known mutations; most of which are located in 
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or near exon 10 [8, 20]. Mutations in MAPT are 
responsible for 3-5% of FTD related diseases, and up 
to 10% of familial FTD (fFTD) [20, 21]. Tau protein 
aggregates are seen in FTDs and also commonly seen 
in AD. Cells with tau positive pathology are rarely 
associated with any of the other known proteins 
involved in frontotemporal neurodegenerative diseases 
[4, 22]. The inclusions in cells with certain tau proteins 
were originally designated as ‘Pick’s bodies’, so this 
type of FTD is also known as Pick, or Pick’s disease 
[23]. Tau pathology is often present when there are no 
mutations in the MAPT gene [24]. Mutations in MAPT 
occur more commonly in AD patients [25]. Mutations in 
MAPT alone may not necessarily cause disease [13]. 
TARDBP  
The non-tau pathology type most commonly 
includes cells with TDP-43 positive inclusions. The 
TDP-43 protein is produced by the TARDBP (trans-
activation response DNA-binding protein) gene located 
on chromosome 1 (1p36.22). The TDP-43 protein is 
known to be involved in DNA and RNA binding and in 
alternative splicing of mRNA. Normal, but 
hyperphosphorylated TDP-43 aggregates are what are 
seen in most FTD related diseases, being present in up 
to 60% of FTD patients, and up to 90% of ALS patients 
[9, 26]. The normal proteins are relocated from the 
nucleus to the cytoplasm and phosphorylation causes 
them to be sequestered in inclusions [27]. Mutations 
may also cause proteins to aggregate, making it 
difficult for the cell to degrade them. These mutations 
are most commonly found in the C-terminal of the 
protein [28, 29]. The normal protein has an intrinsic 
tendency to aggregate via the C-terminal [30]. 
Mutations in TARDBP are most commonly seen in ALS 
patients [1, 2]. Rarely, mutations have been found in 
FTD or FTD with ALS-like symptoms [31], and also 
have been seen in AD, PD and Huntington’s disease 
(HD) [32, 33]. In most diseases involving TDP-43 
pathology there are other abnormal proteins associated 
with the disease process, and there may not be an 
actual mutation in the TARDBP gene. The most 
common of these other proteins include the progranulin 
(produced by the GRN gene) or C9orf72 (produced by 
the C9orf72 gene) proteins, with a rare association with 
the valosin-containing protein (VCP) [34, 35]. For a 
minorityof TDP-43 pathology-associated cases there 
are no other proteins yet known to be involved.  
GRN 
One of the proteins associated with FTD related 
diseases that have TDP-43 pathology is progranulin. 
The GRN gene is located in the hot spot region of 
chromosome 17 (17q21.32). Progranulin is a 
neurotrophic factor that is known to enhance neuronal 
survival [36]. Expression of this protein is regulated by 
proinflammatory Th1 (negative regulation) and Th2 
(positive regulation) [37]. The progranulin protein can 
be cleaved by elastase and other proteases to form 
granulins. Full-length progranulin appears to suppress 
inflammation, while cleaved granulins promote 
inflammation [38]. Mutations have been found in all 
exons (except 13), and most commonly result in a 
progranulin loss of function [5, 39, 40]. Decreased 
amounts of functional progranulin leads to pathological 
processing of TDP-43 by caspase-3, which may 
explain the TDP-43 inclusions [41]. In addition, GRN 
mutations affect the expression of multiple genes in the 
frontal cortex [4]. When the cause is loss of function 
mutations, it’s not enough to try to increase levels of 
functional protein, as this hasn’t been shown to halt cell 
destruction [42]. Over 70 mutations have been found in 
GRN, and account for up to 25% of FTD cases [16, 43]. 
A couple of cases have been noted where there were 
MAPT mutations and GRN mutations, but the cells did 
not have tau pathology [24]. Some rare GRN mutations 
have been found in cases where cells had neither tau 
nor TDP-43 inclusions [44]. 
C9ORF72 
The other major protein associated with FTD related 
diseases that have TDP-43 pathology is C9orf72. The 
name comes from the gene name (C9orf72) as the 
function of this protein has not yet been elucidated, and 
refers to its location on chromosome 9 (9p12.1). Even 
though the existence of this protein’s involvement in 
FTD related diseases has only been known for a few 
years, it is now believed that mutations in this gene are 
responsible for a majority of these diseases [12]. The 
disease causing mutation in this gene is similar to that 
seen in HD; an expanded hexanucleotide (GGGGCC) 
repeat at one end of the gene. The expansion is 
thought to involve the loss of an alternatively spliced 
C9orf72 transcript and result in formation of nuclear 
RNA foci [12, 45]. Other research has shown that the 
hexanucleotide repeats are translated into dipeptide-
repeat proteins that co-aggregate [46]. A normal 
number of repeats is considered to be 20 or fewer, and 
abnormal is 30 repeats or more [47]. The majority of 
non-affected individuals possess 8 repeats or fewer, 
with 2 repeats being by far the most common [2, 48, 
49]. Mutations in C9orf72 have been found in FTD, 
ALS, FTD/ALS or other motor neuron diseases 
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(MNDs), and PD. One study has shown that a repeat 
number of between 20-30 may be a risk factor for 
Parkinson’s [50]. There is also evidence to suggest that 
the number of repeats directly correlates with cellular 
toxicity [51]. One case has been noted that involved a 
patient who was homozygous for expanded repeats, 
but no difference in symptoms was seen compared 
with those who were heterozygous [52]. 
Interestingly, there have been instances where the 
mutation in C9orf72 has been seen without TDP-43 
pathology in FTD and ALS/MND [53, 54]; or without 
TDP-43 pathology, but with tau pathology [55]. There 
are also instances where C9orf72 mutation is seen with 
mutations in some of the other FTD genes: mutation in 
TARDBP in FTD/ALS [56]; mutation in TARDBP and 
FUS in ALS [57, 58]; mutation in GRN in FTD [59-61]; 
and mutation in MAPT in FTD [60].  
VCP 
The VCP gene is located on Chromosome 9p13.3. 
The VCP protein is a member of the ATPase 
associated with diverse cellular activities (AAA) 
superfamily, and phosphorylation is required for its 
activation [62]. The VCP protein has a variety of 
functions, as it is widely expressed. It is well known for 
roles in transporting misfolded proteins from the 
endoplasmic reticulum (ER) to be degraded by the 
proteasome [4, 63]. Loss of VCP leads to a decrease in 
the production of cellular ATP [17]. Rare mutations 
(<1%) in VCP are known to cause FTD and familial 
ALS, and other diseases such as Charcot-Marie-Tooth 
type 2 disease, hereditary spastic paraplegia, inclusion 
body myopathy, and Paget’s disease of the bone [64]. 
At least 24 different mutations have been identified so 
far [63]. In FTD, mutations in VCP are seen with TDP-
43 proteinopathy. It is thought that mutations in VCP 
lead to an alteration in protein function, a decrease in 
proteasome activity, and relocation of TDP-43, which 
lead to the TDP-43 proteinopathy [62].  
FUS 
A small number of cases involve cells that have tau 
negative, TDP-43 negative,and ubiquitin positive 
pathology, and have been found to contain aggregates 
of the fused in sarcoma (FUS) protein. The FUS protein 
has DNA- and RNA-binding functions and shares 
functional homology with TDP-43 [65]. The RNAs that 
are bound by TDP-43 versus those bound by FUS are 
largely distinct [66]. As part of its function, FUS is 
shuttled in and out of the nucleus, and it is involved in 
regulating alternative splicing of proteins related to 
axonal biology [67]. It has been found that 
overexpression of normal FUS protein can cause 
neurodegeneration in mice [68], and cytoplasmic 
inclusions of normal FUS may occur in up to 9% of 
FTD patients [66]; so FUSopathy may be observed with 
or without mutations in FUS [69]. FUS protein 
pathology is usually seen in ALS, PD, and Huntington’s 
disease, and may be seen in a small number of FTDs 
related to ALS and PD [70-72]. The FUSopathies that 
are seen associated with ALS versus FTD differ in 
protein composition [73]. Mutations in FUS are rarely 
seen in FTD (<5%) [43], and are more commonly found 
in ALS [74]. 
CHMP2B 
A very small number of FTD related cases show 
only ubiquitin-based inclusions (tau negative and TDP-
43 negative). These have been found to be associated 
with the charged multivesicular body protein 2B 
(CHMP2B). CHMP2B is a component of the endosomal 
complex [4, 43]. Mutations in CHMP2B have been 
found in a splice site which result in a decreased ability 
of the cell to degrade these proteins [75]. Some 
mutations may result in truncation of the protein at the 
C-terminal [76]. Mutations in this protein may result in 
disassembly of cell structure, increased calcium in the 
endoplasmic reticulum lumen, and a decrease in 
available ATP [77]. Rarely, mutations are associated 
with fFTD and fALS [77-80]. Some very rare cases do 
Table 1: Genetic Pathology of Genes Associated with FTD 
Ubiquinated Inclusions Main Inclusion Protein Other Gene Mutations Involved 
Yes Tau (MAPT) – with or without mutation Usually none 
Yes TDP-43 (TARDBP) – with or without mutation 
GRN 
C9orf72 
VCP 
Yes FUS (FUS) – with or without mutation None 
No None detectable CHMP2B 
8    Journal of Clinical Medicine Research Updates, 2015, Vol. 2 Reygaert 
not seem to have cellular inclusions, and there is little 
information yet on what other genes may be involved 
[43]. 
FTD SYMPTOM GROUPS 
The diagnosis of FTD does not indicate a single 
specific disease. Instead, FTD is a widely varied group 
of disorders that share similar symptoms, and some 
genetic causes as well. These disorders can be loosely 
grouped by early presentation of symptoms (eventually, 
if a patient has FTD long enough, they are more likely 
to exhibit any or all of the symptoms) [12]. There have 
been several excellent attempts to classify these 
symptoms into discrete diagnostic groups [5, 43, 81, 
82]. Because there is so much variation in symptoms, 
even among patients with the same genetic mutation, 
these designated groups are still far from completely 
descriptive. As we learn more about these diseases it 
may become easier (or more difficult) to establish 
symptom groups. For the sake of simplicity, this paper 
will use some very basic group designations. These 
symptom groups are:  
1) Behavioral variant (bvFTD) – loss of inhibition 
or restraint; 
2) Primary progressive aphasia (PPA),which can 
be broken down into two subgroups: 
a) Semantic dementia (svFTD or svPPA) – 
words spoken by the patient indicate a loss of 
word meaning, 
b) Progressive nonfluent aphasia (nfvFTD or 
nfvPPA) – patient loses the ability to speak 
fluently; 
3) Movement disorders (often referred to as 
motor neuron disease – MND) – these 
exhibitsymptoms closely related to Parkinson’s 
and/or ALS; presenting with symptoms such as 
shakiness, muscle dysfunction, and walking and 
balance problems. 
These generalized symptoms groups, and the fact 
that until very recently there was no definitive 
noninvasive testing available for diagnosis, has made 
the diagnosis of FTDs very difficult. Physicians have 
had to rely heavily on descriptions by family and friends 
of the behavior, speech, and movement changes in the 
patient. The use of MRI testing is less helpful early in 
the disease as small changes in the brain may be 
difficult to spot (but should be performed to use as a 
baseline for comparison with later MRIs). 
The bvFTD type is currently considered to be the 
most common early presentation (perhaps because 
behavioral issues may be easier to detect). The 
changes seen may include a variety of socially 
inappropriate behaviors (loss of etiquette and tact, 
restlessness, etc.) that eventually will be very 
discernable when loss of inhibition and restraint lead to 
obsessions such as with sexual issues and, quite often, 
overeating (the patient loses the ability to judge what is 
appropriate in food consumption, and often has an oral 
fixation – wants to put everything in their mouth) [6, 40]. 
In the PPA disorders the emphasis is on changes in 
language. For svFTD, the patient is initially able to 
speak without difficulty, but demonstrates a loss of 
understanding of meaning and comprehension in the 
choice of words, and in interpreting what other people 
say. In nfvFTD, the patient has actual speaking 
difficulties. They may exhibit slow speech or stuttering, 
and may have difficulty finding the correct word to say. 
These patients may also have difficulties in writing and 
reading comprehension [6, 40]. 
The movement disorders related to FTDs are most 
commonly initially mistaken for (although may actually 
be connected with) diseases such as Parkinson’s and 
ALS, as well as other related movement disorders [53, 
78]. Until the disease has progressed (perhaps for 
many years) and symptoms of dementia are seen, an 
accurate diagnosis is difficult. Sometimes these 
patients may be diagnosed as having a movement 
disorder and a separate dementia when what they 
actually have is a form of FTD. Since much more 
research needs to be performed relating to these 
specific movement disorders, this paper will not be 
going into detail on these, except as to how they relate 
directly to FTDs in general. 
These descriptions of the FTDs are not all inclusive, 
and actually the symptom presentation and progression 
of the diseases may involve very complex genetic 
manifestations. This paper will be discussing how some 
of the commonly known genes that may be involved in 
these diseases relate to symptomology, but keep in 
mind that any one patient may actually have mutations 
in more than one of these genes. This can make the 
interpretation of symptom presentation and eventual 
diagnosis a very tricky process. 
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SYMPTOMS ASSOCIATED WITH GENE MUTA- 
TIONS 
This paper will attempt to provide the most common 
initial symptoms associated with each of the genes that 
have been discussed. There is significant variation in 
symptoms even in those individuals who share the 
same mutation. Studies utilizing identical twins (with 
identical mutations) have shown that one twin may get 
the disease and the other not (this is a very rare 
occurrence); more commonly, there are differences in 
age of disease onset (by possibly several years), 
presentation of symptoms, and length of disease 
duration (again, by many years). Interestingly there is 
no significant differences associated with gender [83, 
84]. The diversity of symptoms, age at onset, and 
length of disease are even more varied among family 
members who share the same mutation(s). An example 
of this from one family with two brothers who had FTD 
shows typical diversity. These brothers had a paternal 
grandmother who died with Parkinson’s disease. The 
brothers were two years apart in age. The younger 
brother developed symptoms first at around age 54. 
This brother presented with typical bvFTD which 
progressed slowly until before his death, this brother 
was no longer able to speak or walk. He had the 
disease for 18 years before he died. The older brother 
did not present with detectable symptoms until around 
age 60. His initial symptoms were more like mild 
epilepsy, but within two years he began to exhibit 
memory loss. He then developed more typical bvFTD 
symptoms, but these were followed fairly soon by gait 
issues suggestive of Parkinson’s disease. Very soon 
after that he developed symptoms suggestive of ALS. 
He rapidly became completely nonmobile and died at 
age 72 [data unpublished]. 
Because of these variations the information 
contained here is only a general guideline. One of the 
purposes of this paper is to help scientists and 
clinicians understand the genetic complexities of these 
diseases, and to encourage more genetic testing and 
analysis to further our knowledge on this subject. 
Information on age at onset of disease and disease 
duration/age at death will also be included here. Table 
2 summarizes the genetic and clinical profiles of these 
genes associated with FTD.  
MAPT 
Cellular inclusions of tau are most often associated 
in FTD with bvFTD symptoms, with a small number 
being associated with nfvPPA symptoms [21, 40, 85, 
86]. MAPT has also been associated with FTDs related 
to Parkinson’s and Alzheimer’s, but has not been 
associated with ALS, or MND-type symptoms. 
Mutations in MAPT are more commonly found in AD 
and PD; approximately 19% of PD individuals have a 
mutation in MAPT [87]. The average age of onset of 
tau associated disease is 45 with a range of between 
25-65; and the average years of survival after onset is 
7 with a range of between 2-25 years [84]. 
TARDBP 
Cellular inclusions of TDP-43 are associated with a 
variety of symptoms, depending on whether the 
TARDBP gene contains a mutation, and what other 
abnormal proteins may be present (progranulin, 
C9orf72, VCP, etc.). Mutations in the TARDBP gene 
are associated with AD, ALS, FTD and PD. In ALS and 
PD initial symptoms will usually be MND-related. Age 
at disease onset with mutations in TARDBP is an 
average of 54-56 with a range of 35-74. Average 
disease duration is 6-9 years with a range of 1-21 
years [16, 88]. In FTD the most common initial 
symptom type is bvFTD because that is the most 
common initial symptom for C9orf72 and GRN 
mutations [89], and average age at onset and length of 
disease is related to which other genes and mutations 
are present (see those mutations below). 
GRN 
Mutations in the GRN gene which cause disease 
are almost always associated with TDP-43 pathology 
(the TDP-43 protein in these cases is usually normal). 
There are over 70 different known disease causing 
mutations. These mutations are associated with AD, 
FTD, and PD. In FTD the most common initial symptom 
is bvFTD, with some instances of nfvFTD and svFTD 
as well. Patients who have mutations in both GRN and 
TARDBP usually exhibit bvFTD. The average age at 
disease onset is 56-59 with a range of between 35-83; 
and average length of disease duration is 6-7 years 
with a range of between 1-15 years [16, 84, 90]. 
Recently, testing has been made available for 
measuring progranulin levels in blood serum. The 
blood level of protein in individuals with mutations in 
GRN is much lower than in those without mutations 
[91]. 
C9ORF72 
Mutations in the C9orf72 gene cause the widest 
variation in initial symptoms and disease progression 
10    Journal of Clinical Medicine Research Updates, 2015, Vol. 2 Reygaert 
[92]. Disease is almost always associated with TDP-43 
pathology, and the TDP-43 protein is usually normal. 
Mutations in this gene are now thought to be the most 
common cause of familial cases of FTD and ALS, and 
cause up to 29% of FTD, up to 50% of ALS, and up to 
88% of FTD/ALS [2, 93]. The most common symptom 
at onset is bvFTD [94]. Repeat expansion numbers of 
over 4000 have been found, and one large study found 
a correlation between size of repeat expansion and age 
at onset of disease [95]. The average age at onset of 
disease is 57 with a range of between 33-85; and the 
average length of disease duration is 5 years, with a 
range of between 1-26 years [48, 84]. These wide 
ranges reflect the fact that patients with ALS symptoms 
usually have a much shorter time of disease duration. 
VCP 
Mutations in the VCP gene are very rarely seen in 
FTD disease, and are associated with TDP-43 
pathology. There are at least 24 mutations known to be 
associated with ALS and FTD/ALS [63, 96]. The most 
common initial symptom is bvFTD (around 35%), and 
MND, with other initial symptoms being highly variable. 
Average age of onset of disease is 55 with a range of 
between 37-79; and average length of disease duration 
is 6 years with a range of between 1-21 years [16]. 
FUS 
FUS pathology in cells is not usually associated with 
TDP-43 or tau pathology. The FUS pathology may 
occur with or without mutations in the FUS gene, and 
over 50 mutations have been found that can cause 
disease [74]. FUS pathology has been found in ALS 
and PD, and very rarely in FTD cases [15, 31, 43]. The 
initial symptoms of FTD associated with FUS are nearly 
always bvFTD, with early onset and severe and rapidly 
progressing behavioral issues [1, 16, 97]. The average 
age of onset of disease is 43 with a range of between 
30-60, and the average duration of disease is 3 years 
with a range of between 3-7 years [16]. 
CHMP2B 
Disease associated with CHMP2B mutations are 
also not associated with TDP-43 or tau pathology. 
Mutations are a rare cause of FTD and only a small 
number of mutations have been identified, most 
commonly in familial FTD [16, 78]. The most common 
initial symptom is bvFTD. The average age of onset of 
disease is 58 with a range of between 46-71, and the 
average length of disease duration is 10 years with a 
range of between 5-21 years [16]. 
DISCUSSION 
Unfortunately for medical science, gene inheritance 
is not always a straightforward event. There are many 
factors that affect whether a person receives a mutated 
gene, and especially how that gene is expressed in any 
individual. Often, gene expression is regulated or 
affected by other genes (sometimes many other 
genes), and environmental conditions, for example, 
may also play a role in disease. The symptoms and 
onset of the FTDs and other dementias may vary 
greatly even among people who have the same gene 
mutation. There are differences in age of disease onset 
(by possibly several years), presentation of symptoms, 
and length of disease before death (again, by many 
years). These differences may appear among family 
members who carry the same mutation. These 
observations make it clear that determining if an FTD is 
inherited within a family may be extremely difficult.  
Table 2: Genetic and Clinical Profiles of the Most Common Genes Associated with FTD 
Gene 
No. of Known 
Mutations 
Mutation Frequency in 
FTD 
Most Common 
Initial Symptom 
Mean Age at Onset of 
Symptoms (Range) 
Mean Duration of 
Disease (Range) 
MAPT >50 5-10% bvFTD 45 (22-65) 7 (2-25) 
TARDBP >50 1-3% bvFTD 
depends on associated 
genes 
depends on associated 
genes 
GRN >70 10-20% bvFTD>PPA 57.5 (35-83) 6-7 (1-15) 
C9orf72 
expanded repeat 
>20 
25-30% FTD 
>80% FTD/MND 
bvFTD 57 (33-85) 5 (1-26) 
VCP >20 <1% bvFTD, MND 55 (37-79) 6 (1-21) 
FUS >50 <1% bvFTD 43 (30-60) 3 (3-7) 
CHMP2B 5 <1% bvFTD 58 (46-71) 10 (5-21) 
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There are many genes that are known to be, or 
suspected to be involved in causing FTDs. These 
diseases are not necessarily (and perhaps not very 
often) caused by a mutation in a single gene. Most 
probably there are two or more genes involved 
(scientists have already found this to be so). This 
makes it even more difficult for medical scientists to 
discover which genes may be involved. In addition, 
how these genes are regulated by direct and indirect 
factors adds to the puzzle. This is probably why so 
many of these diseases overlap in symptom 
presentation, etc. 
Will finding the genetic cause of these diseases 
mean that a cure is imminent? Unfortunately, no; but, 
the more that we can find out about the genetic causes, 
the better the chances are that physicians will be able 
to develop targeting therapies. With increased 
knowledge of the mutations and the functions of the 
proteins involved, drug companies should then be able 
to develop treatments that will at least lessen the 
symptoms and delay death, and eventually a cure may 
be found.  
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